Side-by-Side Comparison · 2026

CJC-1295 vs Hexarelin

CJC-1295 vs Hexarelin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?

CJC-1295
Growth Hormone

CJC-1295 is a synthetic GHRH analog with a Drug Affinity Complex (DAC) that binds circulating albumin, extending half-life from 7 minutes to approximately 6-8 days. Enables once-weekly dosing with sustained GH elevation. Phase I/II clinical research status. WADA prohibited under ...

Calculate CJC-1295 dose →
Hexarelin
Growth Hormone

Hexarelin (Examorelin) is the most potent GHRP in clinical research, producing the largest GH pulses per microgram of any peptide in its class. Its methylated tryptophan residue (2-MeTrp) compared to GHRP-6 accounts for its increased potency....

Calculate Hexarelin dose →
Key Parameters
Parameter CJC-1295 Hexarelin
Category Growth Hormone Growth Hormone
Research Extensively Studied Extensively Studied
Half-Life ~6–8 days (with DAC) ~70 min
Typical Dose 1–2 mg 100–200 µg
Frequency Once weekly or twice weekly 1–3× daily
Route Subcutaneous Subcutaneous
FDA Status Not Approved Not Approved

Calculate doses for both

Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.

Calculate CJC-1295 Calculate Hexarelin
Frequently Asked Questions
What is the difference between CJC-1295 and Hexarelin?
CJC-1295: CJC-1295 is a synthetic GHRH analog with a Drug Affinity Complex (DAC) that binds circulating albumin, extending half-life from 7 minutes to approximately 6-8 days. Enables once-weekly dosing with sus... Hexarelin: Hexarelin (Examorelin) is the most potent GHRP in clinical research, producing the largest GH pulses per microgram of any peptide in its class. Its methylated tryptophan residue (2-MeTrp) compared to ...
Which has a longer half-life, CJC-1295 or Hexarelin?
CJC-1295 half-life: ~6–8 days (with DAC). Hexarelin half-life: ~70 min.
Can you stack CJC-1295 and Hexarelin?
CJC-1295 and Hexarelin are in the same category and used together in research protocols. Always consult relevant literature and follow appropriate guidelines.

For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.